Skip to Main Content

Author Details

Steven M Kornblau
The University of Texas MD Anderson Cancer Center
1980
340
82
PMIDPaper TitleJournal TitlePublished Year
36346691Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies.Clin Cancer Res2023
37986997Biologic and clinical features of childhood gamma delta T-ALL: identification of STAG2/LMO2 γδ T-ALL as an extremely high risk leukemia in the very young.medRxiv2023
37575398Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells.Bio Protoc2023
37193700Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.Blood Cancer J2023
37024683DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells.Nat Cell Biol2023
37088806Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.Blood Cancer J2023
37287368Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group.Proteomics Clin Appl2023
37386016A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.Blood Cancer J2023
37183966Ultrasensitive NGS MRD assessment in Ph+â¿¿ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.Am J Hematol2023
36982970DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study.Int J Mol Sci2023
36982555Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia.Int J Mol Sci2023
36982537Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group.Int J Mol Sci2023
37036970Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens.Proc Natl Acad Sci U S A2023
36865338Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses.Res Sq2023
36798219Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.medRxiv2023
36824825Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures.bioRxiv2023
34625713RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences.Leukemia2022
35583199Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.Am J Hematol2022
35610308A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan⿿±⿿clofarabine in allogeneic stem cell transplantation.Bone Marrow Transplant2022
35668135The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness.Nat Cell Biol2022
35533262High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.Blood Adv2022
35589701Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.Nat Commun2022
36518526Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered <i>Runx1</i> splicing.NAR Cancer2022
36467805Protein profiling by reverse phase protein array (RPPA) in classical hairy cell leukemia (HCL) and HCL-variant.EJHaem2022
34980577Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature.Clin Lymphoma Myeloma Leuk2022
35301276Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.Blood Cancer J2022
35021602Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children's Oncology Group study.Haematologica2022
34498444Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase.Haematologica2022
34668451Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.Leuk Lymphoma2022
34719869Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.Proteomics Clin Appl2022
34601571Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.Blood2022
32499238Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.Haematologica2021
33509276Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia.Clin Epigenetics2021
34944883Comparison of the Transcriptomic Signatures in Pediatric and Adult CML.Cancers (Basel)2021
34965151Reverse phase protein arrays in acute leukemia: investigative and methodological challenges.Expert Rev Proteomics2021
34555853Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy.Blood Adv2021
34663807Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.Nat Commun2021
34422660Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes.Front Oncol2021
34329576Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.Lancet Haematol2021
34187466Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival.BMC Med Genomics2021
34351647Development of TP53 mutations over the course of therapy for acute myeloid leukemia.Am J Hematol2021
34103329Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia.Cancer Discov2021
34043428Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol2021
34016956Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.Blood Cancer J2021
33938941Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.Blood Adv2021
34151288Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.Nat Cancer2021
34171128A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.Cancer2021
34280258BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.Blood2021
33212251The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia.J Proteomics2021
33264443Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.Am J Hematol2021
  • 1 - 50 of 340

Recommended Authors

Ashok Kumar Jayavelu
German Cancer Research Center (DKFZ)
Career Start Year 2014
Number of shared co-authors 5
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 15
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 1
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 10
Brett M Stevens
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 3
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 2
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 13
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 3
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 27
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 8
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 10
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 19
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 11
Vivian G Oehler
Fred Hutchinson Cancer Center.
Career Start Year 2003
Number of shared co-authors 20
Phillip M Clair
Huntsman Cancer Institute, The University of Utah
Career Start Year 2001
Number of shared co-authors 13
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 13
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 19
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 14
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 23
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 10
Kolja Eppert
McGill University
Career Start Year 1996
Number of shared co-authors 30
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 14
Mar??a D Odero
University of Navarra
Career Start Year 1994
Number of shared co-authors 5
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 5
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 22
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 22
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 27
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Career Start Year 1989
Number of shared co-authors 18
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 17
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Career Start Year 1984
Number of shared co-authors 28

Collaborators

Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 126
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 64
Jorge Cortes
Georgia Cancer Center
Co-authored papers 62
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 52
Gautam Borthakur
MD Anderson Cancer Center
Co-authored papers 41
Kevin R Coombes
Medical College of Georgia
Co-authored papers 35
Courtney D DiNardo
UT MD Anderson Cancer Center
Co-authored papers 34
Nianxiang Zhang
Co-authored papers 24
Amina A Qutub
University of Texas at San Antonio
Co-authored papers 17
Moshe Talpaz
University of Michigan Rogel Cancer Center.
Co-authored papers 15
Charles G Mullighan
St Jude Children's Research Hospital
Co-authored papers 13
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Co-authored papers 11
Wendy Hu
The University of Texas MD Anderson Cancer Center
Co-authored papers 11
Kathryn G Roberts
St Jude Children's Research Hospital
Co-authored papers 11
Ching-Hon Pui
St. Jude Children's Research Hospital
Co-authored papers 10
Mignon L Loh
University of Washington
Co-authored papers 9
Stephen P Hunger
Children's Hospital of Philadelphia
Co-authored papers 9
Sima Jeha
St. Jude Children's Research Hospital
Co-authored papers 9
Mary V Relling
Departments of Pharmaceutical Sciences.
Co-authored papers 9
Jinghui Zhang
Changhai Hospital, Second Military Medical University
Co-authored papers 8
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 8
Keith A Baggerly
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 7
Todd A Alonzo
Keck School of Medicine, University of Southern California
Co-authored papers 7
Jean-Pierre J Issa
Fels Cancer Institute for Personalized Medicine, Temple University School of Medicine
Co-authored papers 7
Kristine R Crews
St. Jude Children's Research Hospital
Co-authored papers 6
Wei Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Krzysztof Mr??zek
The Ohio State Comprehensive Cancer Center
Co-authored papers 6
Soheil Meshinchi
Fred Hutchinson Cancer Research Centre
Co-authored papers 6
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 6
Release 1.2